Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

20%

Ph not_applicable

20%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

1(25.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 21 (25.0%)

N/A1 (25.0%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

NCT01074840

Clinical Trials (5)

Showing 5 of 5 trials

NCT03345160Phase 2

Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study

Completed

NCT01750879Phase 1

Tolerance Following Peanut Oral Immunotherapy

Completed

NCT02698033

High Threshold Peanut Challenge Study

Completed

NCT01274429Phase 1

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

Terminated

NCT01074840Not Applicable

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5